Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.29 USD 1.83% Market Closed
Market Cap: 842.7m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Accrued Liabilities
$34.2m
CAGR 3-Years
-2%
CAGR 5-Years
15%
CAGR 10-Years
42%
Pharming Group NV
AEX:PHARM
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Accrued Liabilities
€1.4m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Accrued Liabilities
$190.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Accrued Liabilities
$38m
CAGR 3-Years
9%
CAGR 5-Years
65%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Accrued Liabilities
$4.3m
CAGR 3-Years
49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
842.7m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's Accrued Liabilities?
Accrued Liabilities
34.2m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Accrued Liabilities amounts to 34.2m USD.

What is Uniqure NV's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
42%

Over the last year, the Accrued Liabilities growth was -6%. The average annual Accrued Liabilities growth rates for Uniqure NV have been -2% over the past three years , 15% over the past five years , and 42% over the past ten years .

Back to Top